Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. Aug 15, 2014; 5(3): 293-303
Published online Aug 15, 2014. doi: 10.4291/wjgp.v5.i3.293
Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis
Evanthia Zampeli, Michalis Gizis, Spyros I Siakavellas, Giorgos Bamias
Evanthia Zampeli, Gastroenterology Department, Alexandra General Hospital, 11528 Athens, Greece
Michalis Gizis, Spyros I Siakavellas, Giorgos Bamias, Academic Department of Gastroenterology, Ethnikon and Kapodistriakon University of Athens, Laikon Hospital, 15235 Athens, Greece
Author contributions: Zampeli E, Gizis M and Siakavellas SI reviewed the literature; Zampeli E, Gizis M, Siakavellas SI and Bamias G analyzed the data; Zampeli E and Bamias G designed the structure of the review; Zampeli E and Bamias G wrote the paper.
Correspondence to: Giorgos Bamias, Consultant in Gastroenterology, Academic Department of Gastroenterology, Ethnikon and Kapodistriakon University of Athens, 17 Agiou Thoma st., 15235 Athens, Greece. gbamias@gmail.com
Telephone: +30-21-06456504 Fax: +30-21-07791839
Received: January 4, 2014
Revised: March 7, 2014
Accepted: June 10, 2014
Published online: August 15, 2014
Processing time: 242 Days and 18.8 Hours
Core Tip

Core tip: The use of anti-tumor necrosis factor (TNF) monoclonal antibodies for the treatment of ulcerative colitis has been associated with high rates of primary and secondary non-response, important safety issues and considerable cost. Selection of patients with the highest probability to response to anti-TNF treatment would overcome these problems. Analysis of the pivotal trials and accumulated experience from clinical practice has led to the identification of certain prognostic factors for favorable or adverse outcomes. These include clinical and epidemiological parameters, biological markers of inflammation, endoscopic findings, molecular signatures and pharmacological factors. Incorporation of such predictors into the current therapeutic protocols may lead to the optimization of anti-TNF treatment in ulcerative colitis.